Related Experiment Video

Updated: May 12, 2026

Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples
05:17

Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples

Published on: July 28, 2016

Myeloperoxidase G-463A polymorphism and susceptibility to coronary artery disease: a meta-analysis

Naping Tang1, Yan Wang, Qibing Mei

  • 1Department of Pharmacology, School of Life Sciences, Northwestern Polytechnical University, Xi'an, PR China.

Gene
|April 16, 2013
PubMed

Insights

This meta-analysis found that myeloperoxidase (MPO) G-463A polymorphism is associated with a reduced risk of coronary artery disease (CAD). The AA and GA genotypes showed a significant decrease in CAD risk, particularly in Chinese populations.

Area of Science:

  • Genetics and Cardiovascular Disease Research
  • Molecular Epidemiology
  • Biomarker Discovery

Background:

  • Published data on the myeloperoxidase (MPO) G-463A polymorphism and coronary artery disease (CAD) risk are conflicting.
  • A comprehensive meta-analysis is needed to clarify the association between this specific MPO genetic variant and CAD.
  • Understanding genetic predispositions is crucial for personalized cardiovascular risk assessment.

Purpose of the Study:

  • To conduct a meta-analysis to precisely estimate the association between the MPO G-463A polymorphism and CAD.
  • To identify the most likely genetic model for the MPO G-463A polymorphism's effect on CAD.
  • To investigate potential influences of population subgroups and control selection on the observed association.

Main Methods:

  • Systematic literature search of PubMed, EMBASE, and Chinese national knowledge infrastructure databases.
  • Inclusion of studies examining the MPO G-463A polymorphism and its association with CAD.
  • Logistic regression analysis to calculate summary odds ratios (ORs) and 95% confidence intervals (CIs) for different genotypes.

Main Results:

  • Strong evidence supports an association between the MPO G-463A polymorphism and CAD.
  • The co-dominant genetic model best explained the observed effects.
  • Significantly reduced CAD risk was observed for AA and GA genotypes compared to GG (OR=0.37 and OR=0.73, respectively).
  • Subgroup analyses revealed significant protective effects in Chinese populations and hospital-based control studies.

Conclusions:

  • The MPO G-463A variant genotypes are associated with a decreased risk of coronary artery disease.
  • The protective effect is particularly notable in individuals with AA and GA genotypes.
  • Further research is warranted to confirm these findings due to study limitations and potential biases.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...